207 related articles for article (PubMed ID: 21373642)
21. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
22. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
23. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
24. Lycopene and apo-10'-lycopenoic acid have differential mechanisms of protection against hepatic steatosis in β-carotene-9',10'-oxygenase knockout male mice.
Ip BC; Liu C; Lichtenstein AH; von Lintig J; Wang XD
J Nutr; 2015 Feb; 145(2):268-76. PubMed ID: 25644347
[TBL] [Abstract][Full Text] [Related]
25. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
[TBL] [Abstract][Full Text] [Related]
26. Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
Gao M; Ma Y; Alsaggar M; Liu D
AAPS J; 2016 Jul; 18(4):1023-31. PubMed ID: 27125895
[TBL] [Abstract][Full Text] [Related]
27. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice.
Kong Q; Zhang H; Zhao T; Zhang W; Yan M; Dong X; Li P
Int J Mol Med; 2016 Dec; 38(6):1715-1726. PubMed ID: 27840945
[TBL] [Abstract][Full Text] [Related]
28. Daming capsule, a hypolipidaemic drug, lowers blood lipids by activating the AMPK signalling pathway.
Bian Y; Li X; Li X; Ju J; Liang H; Hu X; Dong L; Wang N; Li J; Zhang Y; Yang B
Biomed Pharmacother; 2019 Sep; 117():109176. PubMed ID: 31387185
[TBL] [Abstract][Full Text] [Related]
29. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.
Magenta G; Borenstein X; Rolando R; Jasnis MA
BMC Cancer; 2008 Feb; 8():47. PubMed ID: 18261208
[TBL] [Abstract][Full Text] [Related]
30. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice.
Sun X; Tang Y; Tan X; Li Q; Zhong W; Sun X; Jia W; McClain CJ; Zhou Z
Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G548-57. PubMed ID: 22173916
[TBL] [Abstract][Full Text] [Related]
31. Methyl ferulic acid attenuates ethanol-induced hepatic steatosis by regulating AMPK and FoxO1 Pathways in Rats and L-02 cells.
Cheng Q; Li YW; Yang CF; Zhong YJ; He H; Zhu FC; Li L
Chem Biol Interact; 2018 Aug; 291():180-189. PubMed ID: 29940154
[TBL] [Abstract][Full Text] [Related]
32. Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice.
Choi BH; Jin Z; Yi CO; Oh J; Jeong EA; Lee JY; Park KA; Kim KE; Lee JE; Kim HJ; Hahm JR; Roh GS
PLoS One; 2018; 13(7):e0200336. PubMed ID: 29979770
[TBL] [Abstract][Full Text] [Related]
33. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
[TBL] [Abstract][Full Text] [Related]
34. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
35. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Gavrilova O; Haluzik M; Matsusue K; Cutson JJ; Johnson L; Dietz KR; Nicol CJ; Vinson C; Gonzalez FJ; Reitman ML
J Biol Chem; 2003 Sep; 278(36):34268-76. PubMed ID: 12805374
[TBL] [Abstract][Full Text] [Related]
36. Micheliolide alleviates hepatic steatosis in db/db mice by inhibiting inflammation and promoting autophagy via PPAR-γ-mediated NF-кB and AMPK/mTOR signaling.
Zhong J; Gong W; Chen J; Qing Y; Wu S; Li H; Huang C; Chen Y; Wang Y; Xu Z; Liu W; Li H; Long H
Int Immunopharmacol; 2018 Jun; 59():197-208. PubMed ID: 29656210
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor γ activation ameliorates liver fibrosis-differential action of transcription factor EB and autophagy on hepatocytes and stellate cells.
Yum YJ; Yoo J; Bang K; Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC
Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37204406
[TBL] [Abstract][Full Text] [Related]
38. PPAR-γ agonist ameliorates liver pathology accompanied by increasing regulatory B and T cells in high-fat-diet mice.
Xu Z; Wang G; Zhu Y; Liu R; Song J; Ni Y; Sun H; Yang B; Hou M; Chen L; Ji M; Fu Z
Obesity (Silver Spring); 2017 Mar; 25(3):581-590. PubMed ID: 28150448
[TBL] [Abstract][Full Text] [Related]
39. PPAR-γ agonist rosiglitazone reverses perinatal nicotine exposure-induced asthma in rat offspring.
Liu J; Sakurai R; Rehan VK
Am J Physiol Lung Cell Mol Physiol; 2015 Apr; 308(8):L788-96. PubMed ID: 25659902
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism.
Lee MY; Choi R; Kim HM; Cho EJ; Kim BH; Choi YS; Naowaboot J; Lee EY; Yang YC; Shin JY; Shin YG; Chung CH
Exp Mol Med; 2012 Oct; 44(10):578-85. PubMed ID: 22824914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
